Pharmacists can play an important role in educating patients about poison prevention tips during the pandemic, and discuss the dangers of home remedies.
Pharmacy Times’ parent company will be hosting the virtual MJH Life Sciences Sleeves Up Blood Drive from March 31 through April 30.
A recent study has detailed information on the potential dangers and the application of QTc monitoring to guide treatment when using drugs that can cause heart rhythm changes.
The length of time patients remained contagious after the end of their symptoms, however, ranged from 1 to 8 days.
"We are trying to stay strong, and we couldn’t cope with this situation if it wasn’t for our deep team connection.”
A study by the American Academy of Neurology suggests that taking a low-dose aspirin once per day does not reduce the risk of thinking and memory problems caused by mild cognitive impairment or possible Alzheimer disease.
A new study examining records from the Ohio Health Department from 2010 to 2017 found that white men between the ages of 30 and 39 had the highest risk for fatal opioid overdoses.
While the drugs are not currently FDA-approved for COVID-19, the FDA noted that they are recommended in some countries for COVID-19.
SIDP Reminds Public to Have ‘Proper Information About the Safety, Efficacy of Medications’ During COVID-19 Pandemic
Members of the Society of Infectious Diseases Pharmacists (SIDP) have been on the forefront of the pandemic, reviewing treatment data and assisting in interpretation for clinical use.
How has COVID-19 affected our lives?
Researchers examine how stem cells promote neuronal growth in tissue regeneration and in cancer progression.
In the midst of rapid industry changes and new demands brought by the coronavirus disease 2019 pandemic, pharmacy technicians are taking on new roles and responsibilities.
A prespecified exploratory analysis using the safety data from the 3 trials indicated fewer major adverse cardiovascular events (MACE) with inclisiran compared with placebo.
According to the researchers, the case fatality rate for patients with COVID-19 and cardiovascular disease is 10.5%.
Further, these natural killer (NK) cells appear to be more effective the earlier they are in development, creating the possibility of an immunotherapy that would not use cells from a patient or a matched donor.